



No. *68*/CV-BCTC-DHT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, July 28, 2026

To: The State Securities Commission of Viet Nam
Hanoi Stock Exchange

Company name: Ha Tay Pharmaceutical Joint Stock Company

Stock Code: DHT

Head office: 10A Quang Trung – Ha Dong Ward – Hanoi City

Phone: 0433 501 117 – Fax: 0433 829 054

Information disclosure officer: Mrs. Pham Minh Thu – Deputy Manager of Legal and Communications Department.

In the Consolidated financial statements for Q2 2026, the business results of Hatay Pharmaceutical Joint Stock Company are as follows:

The total profit after tax in Q2 2026 was VND 11.409.975.718, compared to VND 13.408.687.822 in Q2 2025 — a decrease of VND 1.998.712.104, equivalent to a drop of 14.91% This was mainly due to:

- Gross profit in the Q2 in 2026 amounted to VND 51,319,928,919, compared to VND 51,099,341,904 in the Q2 in 2025, representing an increase of VND 220,587,015.
- Financial income in the Q2 in 2026 amounted to VND 4,640,393,405, compared to VND 5,660,632,622 in the Q2 in 2025, representing a decrease of VND 1,020,239,217, or 18.02%. The decline in financial income had an adverse impact on the Company's profit for the period.
- Selling expenses and general and administrative expenses in the Q2 in 2026 totaled VND 40,945,408,110, compared to VND 36,921,558,738 in the Q2 in 2025, representing an increase of VND 4,023,849,372, or 11%. The increase in selling expenses and general and administrative expenses negatively affected the Company's profit for the period.
- Corporate income tax expense for the Q2 in 2026 amounted to VND 3,632,813,461, compared to VND 2,928,429,738 in the Q2 in 2025, representing an increase of VND 704,383,723, or 24%. The higher corporate income tax expense reduced the Company's profit after tax for the period.

We hereby report to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for your information.

Recipient:

- As above

- Archive: Office files

HA TAY PHARMACEUTICAL JOINT STOCK
COMPANY

General Director



Osamu Yomogida
Osamu Yomogida